Abstracts tagged "biologic response modifiers"

Abstract Number: 0831 • ACR Convergence 2023
Two- and Three-Year Outcomes from the Childhood Arthritis and Rheumatology Research Alliance Start Time Optimization of Biologic Therapy in Polyarticular JIA (STOP-JIA) Study
Sarah Ringold¹, George Tomlinson², Laura Schanberg³, vincent del gaizo⁴, Katherine Murphy⁵, Brian Feldman⁶, Mei-Sing Ong⁷, Marc Natter⁸, Yukiko Kimura⁹ and For The CARRA Registry Investgators⁴, ¹Seattle Children's Hospital, Seattle, WA, ²University of Toronto, Toronto, ON, Canada, ³Duke University School of Medicine, Durham, NC, ⁴CARRA, Inc, Washington, DC, ⁵Non-clinical, New Orleans, LA, ⁶The Hospital for Sick Children, Toronto, ON, Canada, ⁷Harvard Medical School & Harvard Pilgrim Healthcare Institute, Boston, MA, ⁸Harvard Medical School, Boston, MA, ⁹Hackensack Meridian School of Medicine, New York, NY
Background/Purpose: The STOP-JIA study was designed to compare the effectiveness of the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Consensus Treatment Plans (CTPs) for untreated…
Abstract Number: 0264 • ACR Convergence 2022
Reasons for Early Discontinuation of Targeted Synthetic (ts) or Biologic (b) DMARDs; Chart Review of 20,343 Drug Episodes Given to Patients with Rheumatoid Arthritis
Kent Kwas Huston¹, Christopher Adams², Simon Helfgott³, Jasvinder singh⁴, Nehad Soloman⁵, Dan Persons⁶, Scott Milligan⁶ and Colin Edgerton², ¹Kansas City Physician Partners Center for Rheumatic Disease, Kansas City, MO, ²Articularis Healthcare, Sullivans Island, SC, ³Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ⁴University of Alabama at Birmingham, Birmingham, AL, ⁵Arizona Arthritis & Rheumatology Associates, P.C., Peoria, AZ, ⁶Trio Health, Louisville, CO
Background/Purpose: The development, exacerbation, or unimprovement of clinical conditions during DMARD treatment may lead patients to abandon treatment before the necessary time has elapsed for…
Abstract Number: 1436 • ACR Convergence 2022
Predictors at Diagnosis for Start of Biologic Disease Modifying Anti-Rheumatic Drugs in Patients with Early Rheumatoid Arthritis
Mohaned Hameed¹, Sofia Exarchou¹, Anna Eberhard¹, Ankita Sharma¹, Ulf Bergström¹, Jon Einarsson² and Carl Turesson³, ¹Lund University, Malmö, Sweden, ²Skåne University Hospital, Lund, Sweden, ³Rheumatology, Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden
Background/Purpose: With increasing use of biologic disease modifying anti-rheumatic drugs (bDMARDs) and targeted synthetic DMARDs (tsDMARDs) for the management of rheumatoid arthritis (RA), outcomes have…
Abstract Number: 1606 • ACR Convergence 2022
An Expanded Anti-citrullinated Protein Antibody Profile Derived Using Unsupervised Machine Learning Predicts Treatment Responses to Biologic Therapies in Rheumatoid Arthritis
nozima Aripova¹, George Reed², Bryant England¹, William Robinson³, Dimitrios Pappas⁴, Joel Kremer⁵, Geoffrey Thiele¹ and Ted Mikuls⁶, ¹University of Nebraska Medical Center, Omaha, NE, ²The Corrona Research Foundation and University of Massachusetts, Albany, NY, ³Stanford University School of Medicine, Palo Alto, CA, ⁴CorEvitas, LLC, Waltham, MA, ⁵The Corrona Research Foundation, Delray Beach, FL, ⁶Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Rheumatoid arthritis (RA) treatments have advanced with the availability of biologic therapies. Despite these advances, 30-40% of patients receiving a biologic do not adequately…
Abstract Number: 1679 • ACR Convergence 2022
The Childhood Arthritis and Rheumatology Research Alliance Start Time Optimization of Biologic Therapy in Polyarticular JIA (STOP-JIA) Study: Three-Year Outcomes
Yukiko Kimura¹, Sarah Ringold², George Tomlinson³, Laura Schanberg⁴, Anne Dennos⁵, MaryEllen Riordan⁶, Vincent Del Gaizo⁷, Katherine Murphy⁸, Pamela Weiss⁹, Brian Feldman¹⁰, Mei Sing Ong¹¹ and Marc Natter¹², ¹Hackensack Meridian Health, New York, NY, ²Janssen, Seattle, WA, ³University of Toronto, Toronto, ON, Canada, ⁴Duke University Medical Center, Durham, NC, ⁵Duke University, Durham, NC, ⁶Hackensack Meridian Health, Hackensack, NJ, ⁷CARRA, Inc, Washington, DC, ⁸CARRA, Inc, New Orleans, LA, ⁹Children's Hospital of Philadelphia, Glen Mills, PA, ¹⁰Division of Rheumatology, The Hospital for Sick Children; Child Health Evaluative Services, SickKids Research Institute; Department of Paediatrics, University of Toronto, Toronto, ON, Canada, ¹¹Harvard Pilgrim Institute, Boston, MA, ¹²Boston Children's Hospital, Boston, MA
Background/Purpose: The CARRA STOP-JIA study compared the effectiveness of the CARRA Consensus Treatment Plans (CTPs) in achieving clinically inactive disease (CID) in untreated polyarticular JIA…
Abstract Number: 0818 • ACR Convergence 2021
Biologics Initiation in Moderate vs Severe Rheumatoid Arthritis Patients: Prospective Observational Study from a Canadian Registry
Nancy Guo¹, Xiuying Li², Mohammad Movahedi³, Angela Cesta⁴ and Claire Bombardier⁵, ¹Kingston General Hospital, Kingston, ON, Canada, ²OBRI at University Health Network, Toronto, ON, Canada, ³Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada, ⁴Toronto General Hospital Research Institute, UHN, Toronto, ON, Canada, ⁵University of Toronto - Toronto, Toronto, ON, Canada
Background/Purpose: Prior studies have shown that in the real-world setting, rheumatoid arthritis (RA) patients have lower disease activity than those studied in clinical trials. However,…
Abstract Number: 1217 • ACR Convergence 2021
Discontinuation Rate of Tofacitinib Is Similar When Compared to TNF Inhibitors in Rheumatoid Arthritis Patients: Pooled Data from Two Rheumatoid Arthritis Registries in Canada
Mohammad Movahedi¹, Denis Choquette², Louis Coupal², Angela Cesta³, Xiuying Li³, Edward Keystone⁴ and Claire Bombardier⁵, ¹Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada, ²Institut de Rhumatologie de Montréal, Montréal, QC, Canada, ³Toronto General Hospital Research Institute, UHN, Toronto, ON, Canada, ⁴Keystone Consulting Enterprises Inc., Toronto, ON, Canada, ⁵University of Toronto - Toronto, Toronto, ON, Canada
Background/Purpose: Tofacitinib (TOFA) is an oral, small molecule drug used for rheumatoid arthritis (RA) treatment as the first or an alternative option to biologic disease-…
Abstract Number: 1219 • ACR Convergence 2021
Machine Learning Based Prediction Model for Responses of bDMARDs in Patients with Rheumatoid Arthritis and Ankylosing Spondylitis
Seulkee Lee, Seonyoung Kang, Yeonghee Eun, Hyungjin Kim, Jaejoon Lee, Eun-Mi Koh and Hoon-Suk Cha, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea
Background/Purpose: Few studies on rheumatoid arthritis (RA) have generated machine learning models to predict biologic disease-modifying antirheumatic drugs (bDMARDs) responses; however, these studies included insufficient…
Abstract Number: 1732 • ACR Convergence 2021
Effects of B Cell Activating Factors/B Lymphocyte Stimulator Inhibitors Added to Standard of Care on Infection in Patients with Systemic Lupus Erythematosus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Ruoning Ni¹, Jiayi Zheng² and Ruru Guo³, ¹Saint Agnes Healthcare, Baltimore, MD, ²Department of Rheumatology, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China (People's Republic), ³Renji Hospital, Shanghai, China (People's Republic)
Background/Purpose: The efficacy of B cell activator factor/B lymphocyte stimulator inhibitors (BAFFi/BLySi) for systemic lupus erythematosus (SLE) has been proven in clinical trials. However, it…
Abstract Number: 1240 • ACR Convergence 2020
An Increase in Red Cell Mean Corpuscular Volume by Methotrexate Is Potentiated by Hydroxychloroquine and Predicts Clinical Response in Rheumatoid Arthritis
Muhammad Shipa¹, Su-Ann Yeoh¹, Dev Mukerjee² and Michael Ehrenstein¹, ¹University College London, LONDON, United Kingdom, ²North Middlesex University hospital NHS Trust, London, United Kingdom
Background/Purpose: Methotrexate (MTX) can result in an increase in mean corpuscular volume (MCV) of red blood cells. The range of MCV change varies between patients…
Abstract Number: 1376 • ACR Convergence 2020
Impact of Body Composition Measures on the Response to Biological Disease-modifying Anti-rheumatic Drugs in Patients with Ankylosing Spondylitis
Valeria Rios Rodriguez¹, Mikhail Protopopov¹, Fabian Proft¹, Judith Rademacher¹, Burkhard Muche¹, Anne-Katrin Weber¹, Susanne Lüders¹, Hildrun Haibel¹, Maryna Verba¹, Joachim Sieper¹ and Denis Poddubnyy², ¹Charité Universitätsmedizin Berlin, Berlin, Germany, ²Charité – Universitätsmedizin Berlin, Berlin, Germany
Background/Purpose: Data on the impact of body weight and body mass index (BMI) on the response to biological disease-modifying anti-rheumatic drugs (bDMARDs) in axial spondyloarthritis…
Abstract Number: 1898 • ACR Convergence 2020
Comparative Effectiveness of Secukinumab, Adalimumab and Other Tumor Necrosis Factor Inhibitors in the Treatment of Axial Spondyloarthritis
Loïc Choquette Sauvageau¹, Denis Choquette², Louis Bessette³, Isabelle Ferdinand¹, Boulos Haraoui⁴, Frédéric Massicotte¹, Jean-Pierre Pelletier², Jean-Pierre Raynauld², Marie-Anaïs Rémillard¹, Diane Sauvageau¹, Édith Villeneuve¹ and Louis Coupal¹, ¹Institut de Rhumatologie de Montréal, Montréal, QC, Canada, ²Institut de Rhumatologie de Montréal, Montreal, Canada, ³Centre de l'Ostéoporose et de Rhumatologie de Québec, Quebec, QC, Canada, ⁴Rheumatology Institute of Montréal, Montreal, Canada
Background/Purpose: Studies comparing the effectiveness of biologics in the treatment of axial spondyloarthritis (axSpA) are sparse [1]. One study comparing secukinumab and adalimumab biosimilar is ongoing.…
Abstract Number: 2005 • ACR Convergence 2020
Histo-pathological Cellular Markers of Treatment Response to Rituximab and Tocilizumab in Matched Pre- and Post-treatment Synovial Biopsies from the R4RA Randomised Clinical Trial in Rheumatoid Arthritis
Felice Rivellese¹, Frances Humby², Giovanni Giorli², Alessandra Nerviani¹, Rebecca Hands², Liliane Fossati-Jimack², Georgina Thorborn², Myles Lewis¹ and Costantino Pitzalis², ¹Centre for Experimental Medicine and Rheumatology, Queen Mary University of London, London, United Kingdom, ²Queen Mary University of London, London, United Kingdom
Background/Purpose: The results of the R4RA trial, the first biopsy-based RCT in TNF-i inadequate responders patients with Rheumatoid Arthritis (RA), showed that molecular stratification of…
Abstract Number: 2032 • ACR Convergence 2020
Treatment Response to Biological Disease-modifying Anti-rheumatic Drugs Is Associated with Favorable Changes of the Body Composition in Patients with Ankylosing Spondylitis
Valeria Rios Rodriguez¹, Mikhail Protopopov¹, Fabian Proft¹, Judith Rademacher¹, Burkhard Muche¹, Anne-Katrin Weber¹, Susanne Lüders¹, Hildrun Haibel¹, Maryna Verba¹, Joachim Sieper¹ and Denis Poddubnyy², ¹Charité Universitätsmedizin Berlin, Berlin, Germany, ²Charité – Universitätsmedizin Berlin, Berlin, Germany
Background/Purpose: There is few data available regarding differences in body composition and its possible changes in patients with ankylosing spondylitis (AS) treated with biological disease-modifying…
Abstract Number: 0227 • ACR Convergence 2020
Real Life Severe Infections in Patients with Rheumatoid Arthritis on Treatment with Biological Therapy and JAK Inhibitors
Lucía Vega-Álvarez¹, Itziar Calvo-Zorrilla¹, Oihane Ibarguengoitia-Barrena¹, Juan M. Blanco-Madrigal¹, David Montero-Seisdedos², Carmen L. Garcia-Gomez¹, Maria Esther Ruiz-Lucea¹, Ana R. Inchaurbe-Pellejero¹, Ignacio Torre-Salaberri¹, Clara E. Perez-Velasquez¹, Olaia Fernandez-Berrizbeitia¹, Eduardo Cuende-Quintana³, Iñigo R. Gorostiza-Hormaetxe⁴, María Luz García-Vivar¹ and Eva Galindez-Agirregoikoa¹, ¹Basurto University Hospital, BILBAO, Spain, ²Basurto University Hospital, Bilbao, Pais Vasco, Spain, ³Basurto University Hospital, Madrid, Spain, ⁴Basurto University Hospital, Bilbao
Background/Purpose: Infections are one of the main complications among patients with rheumatoid arthritis (RA) with immunosuppressive treatment. The differences between treatments and the influence of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].